Target intelligence / Profile preview

Genitourinary microbiota

Molecular classification
Other (specifically, community of microorganisms—bacteria, fungi, archaea—not a molecular class)
01

Overview

The **genitourinary microbiota** comprises diverse microorganisms—including bacteria such as *Lactobacillus*, *Gardnerella*, coagulase-negative *Staphylococcus*, *Streptococcus*, and various anaerobes—residing in the urinary tract (kidneys, bladder, urethra) and genital tract mucosa. This microbial ecosystem contributes to local health by inhibiting pathogens, maintaining mucosal barrier function, and modulating the immune milieu. Disruption (dysbiosis) of the genitourinary microbiota is associated with increased risk for urinary tract infections (UTIs), recurrent cystitis, and possibly other complications such as bladder dysfunction and antibiotic resistance. Recent research considers the microbiota itself as a therapeutic "ecosystem" target, approached with interventions such as probiotics and FMT, but the microbiota itself is not a defined molecular target in the conventional pharmacologic sense[1][2][3][4][6].

Other names
Urinary microbiomeUrogenital microbiomeUrogenital microbiotaLower genitourinary tract microbiome
02

Mechanism of action

Restoration or modulation of microbial community (ecological restoration); Inhibition of pathogenic bacterial growth and adhesion (by probiotics); Immunomodulation (by specific strains, e.g., secretion of immunomodulatory proteins from *Lactobacillus*).

03

Biological functions

Maintenance of mucosal and epithelial healthProtection against pathogenic colonization (colonization resistance)Modulation of immune response and inflammationHomeostasis of local pH and metabolic environment
04

Disease associations

Infection (Urinary tract infection, recurrent cystitis)Other (implicated in bladder health, neurogenic bladder, possibly cancer and inflammatory states)
05

Safety considerations

Disruption of microbiota by antibiotics leading to increased infection risk and antimicrobial resistanceProbiotics are generally safe, but detailed risks not well characterized; FMT carries potential infectious and psychological risks
06

Interacting drugs

Probiotics (e.g., *Lactobacillus* spp. capsules, vaginal suppositories, intravesical instillation)

2 more in the full profile.

07

Biomarkers

Relative abundance of *Lactobacillus* spp. (associated with health/protection)Presence or overgrowth of uropathogens (e.g., *Escherichia coli*, *Klebsiella* spp.)Shifts in microbial diversity (dysbiosis vs eubiosis)

Beyond the preview

Go deeper on Genitourinary microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genitourinary microbiota.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call